Loading...
•
Dec 31, 2023
Replimune Q3 2024 Earnings Report
Replimune reported financial results for the fiscal third quarter ended December 31, 2023.
Key Takeaways
Replimune's existing cash, cash equivalents and short-term investments, as of December 31, 2023, will enable the Company to fund operations into the second half of 2026.
RP1 data shows potential as a safe and effective treatment for various skin cancers.
BLA submission planned for anti-PD1 failed melanoma in 2H 2024.
Clinical trial planned for advanced uveal melanoma to establish a rare cancer franchise.
Cash runway extended to fund operations into 2H 2026 following pipeline reprioritization.
Replimune
Replimune
Forward Guidance
Based on the current operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of December 31, 2023, will enable the Company to fund operations into the second half of 2026.